Clinical course of ST elevation myocardial infarction and blood leptin levels

Abstract

Recently, researchers have been increasingly interested in the association between the incidence of cardiovascular events (such as myocardial infarction, MI) and leptin – an adipocyte-produced hormone, which normally is involved in the body mass regulation. Aim. To assess the role of leptin in the clinical course of acute myocardial infarction with ST segment elevation (STEMI) on ECG. Material and methods. The study included 89 men aged 23–77 years. All patients underwent coronary angiography (CAG) in the first 12 hours of STEMI. Based on the CAG findings, 80 patients underwent percutaneous coronary interventions (PCI). All participants were divided into two groups, based on the plasma levels of leptin. Group 1 (n=42) had elevated leptin levels (>5,63 ng/ml), while Group 2 (n=47) had normal leptin levels (<5,63 ng/ml). Results. In MI patients, leptin concentration was a predictor of the in-hospital diagnosis of Type 2 diabetes mellitus (DM-2). The plasma leptin concentration in the first 24 hours of MI was associated with the levels of interleukin-1-beta, potassium, creatinine, triglycerides, haemoglobin, body mass index, and left ventricular enddiastolic dimension. Conclusion. Leptin levels in the acute phase of STEMI could be used for the prediction of MI complications and DM-2.

Keywords

• leptin
• risk factor
• predictor
• cardiovascular pathology
• myocardial infarction, percutaneous coronary interventions
• chronic kidney disease
• diabetes mellitus